Premium
CNS recurrence following CD34 + peripheral blood stem cell transplantation in stage 4 neuroblastoma
Author(s) -
Choi Hyoung Soo,
Koh Sang Hyeok,
Park Eun Sil,
Shin Hee Young,
Ahn Hyo Seop
Publication year - 2005
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20315
Subject(s) - medicine , etoposide , neuroblastoma , carboplatin , melphalan , blood cancer , transplantation , chemotherapy , cd34 , stage (stratigraphy) , autologous stem cell transplantation , stem cell , oncology , surgery , cancer , cisplatin , paleontology , biology , genetics , cell culture
We report here central nervous system (CNS) recurrence in neuroblastoma (NBL) after CD34 + peripheral blood stem cell transplantation (PBSCT). Fifteen stage 4 NBL patients underwent CD34 + transplantation with myeloablative chemotherapy consisting of carboplatin, etoposide, and melphalan. There were three primary site recurrences and five distant metastases including four brain metastases (two isolated CNS recurrences) at 4–7 months after CD34 + transplantation. Three of four patients died of CNS progressive disease at 2, 8, and 9 months after recurrence and the remaining single patient was lost to follow‐up. CNS recurrence in NBL is fatal and requires identification of risk factors and more effective treatment strategies. Pediatr Blood Cancer 2005; 45:68–71. © 2005 Wiley‐Liss, Inc.